特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

注射型ドラッグデリバリーの世界市場:市場規模、シェア、発展、成長、需要予測

Global Injectable Drug Delivery Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

発行 Occams Business Research & Consulting Pvt. Ltd. 商品コード 536397
出版日 ページ情報 英文 190 Pages
納期: お問合せ
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
注射型ドラッグデリバリーの世界市場:市場規模、シェア、発展、成長、需要予測 Global Injectable Drug Delivery Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023
出版日: 2017年07月26日 ページ情報: 英文 190 Pages
概要

当レポートでは注射型ドラッグデリバリーの世界市場について調査し、全体的な市場動向、タイプ・治療的適用・利用パターン・エンドユーザー・地域別の詳細動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 市場概要

  • 注射型ドラッグデリバリーの世界市場:発展と変遷
  • 市場の定義・範囲
  • 産業構造
  • 規制の枠組み
  • 市場分析
    • 調査結果
    • 市場機会
    • 主要企業
    • 戦略
  • 予測分析
  • 戦略分析
    • 投資 vs 導入モデル
    • 全方位的分析
    • ファイブフォース分析
    • シーソー理論
    • 顧客分析・購買基準
  • 競合分析
    • 戦略の分析
    • 市場シェアの分析
  • 戦略提言
    • 投資機会:地域別
    • 新用途における市場機会
    • 最速成長市場における投資機会

第3章 市場の決定要因

  • 促進要因
  • 阻害要因
  • 機会
  • 課題

第4章 市場区分

  • 注射型ドラッグデリバリー市場:タイプ別
    • 注射型ドラッグデリバリー向けデバイス
    • 注射型ドラッグデリバリー向け製剤
  • 注射型ドラッグデリバリー市場:製剤別
    • アンプル入り製剤
    • ボトル入り製剤
    • カートリッジ入り製剤
    • バイアル入り製剤
  • 注射型ドラッグデリバリー市場:治療的適用別
    • 免疫疾患
    • 内分泌疾患
    • 希少疾患
    • その他
  • 注射型ドラッグデリバリー市場:利用パターン別
    • 根治治療
    • 免疫治療
    • その他
  • 注射型ドラッグデリバリー市場:エンドユーザー別
    • 病院
    • 在宅ケア
    • その他(研究機関、臨床診断ラボ)

第5章 競合情勢

  • 主な戦略
    • 合併・買収
    • 合弁事業
    • 新製品の投入
    • パートナーシップ

第6章 地域分析

  • 意思決定支援データベース
  • 産業間の比較分析
  • 市場機会のマトリクス
  • 注射型ドラッグデリバリーの世界市場:地域別
    • 北米
      • 産業分析
      • 国別
    • 欧州
      • 産業分析
      • 国別
    • アジア太平洋
      • 産業分析
      • 国別
    • その他の地域
      • 産業分析
      • 国別

第7章 企業プロファイル

目次
Product Code: HPH-6530817

Injectable drug delivery is used for direct introduction of a pharmaceutical drug in body of the patient with the help of a delivery device. The global inject able drug delivery market is expected to rise at a CAGR of 12% during the forecast period 2016-2023. Growth in pharmaceutical and biotechnology industry is contributing to the growth of the global inject able drug delivery market. However, infection associated with needle stick injury is the factor restraining the growth of the global inject able drug delivery market during the forecast period.

Geographically, North America accounted for the largest market share in terms of revenue for inject able drug delivery market in 2016 and the region is expected to dominate the market during the forecast period followed by Europe. The dominance of the region is attributed to technologically advanced healthcare facilities in the countries of the region. However, Asia Pacific is expected to be the fastest growing region for inject able drug delivery market during the forecast period. The highest growth in the region is observed due to enhancing healthcare infrastructure and prevalence of chronic diseases in the region.

The growth in global inject able drug delivery market is also influenced by the presence of major players such as Baxter International (U.S.), Schott AG (Germany), Terumo Corporation (U.S.), Hospira Inc. (U.S.), Sanofi SA (France) etc. The market players adopt some crucial strategies such as product launches, partnerships, mergers & acquisitions etc.to gain competitive advantage.

Global inject able drug delivery market report covers segmentation analysis of type, formulation, therapeutic application, usage pattern and end users. Report further covers segmentsof type which includes device and formulations. Device is expected to dominate the segment during the forecast period owing to rising usage in management and control of various disorders at primary level. Formulation packaging in inject able drug delivery is divided as ampoules, bottles, cartridges and vials. Moreover, therapeutic applications of inject able drug delivery include auto immune diseases, hormonal disorders, oncology, orphan diseases and other applications. Oncology is expected to dominate the segment during the forecast period owing to increasing application of inject able drug delivery in diagnosis and treatment of cancer and diabetes. Furthermore, usage pattern segment of inject able drug delivery can be sub divided as curative care, immunization and others. Also, end users of inject able drug delivery include hospitals, homecare and others (Research institutes, clinical, diagnostic laboratories). Homecare segment is expected to dominate the segment during the forecast period owing to increasing demand for self-injection devices which provides easy administration of drugs at home without medical assistance.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. EXECUTIVE SUMMARY
  • 1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW

  • 2.1. INJECTABLE DRUG DELIVERY MARKET: EVOLUTION & TRANSITION
  • 2.2. MARKET DEFINITION & SCOPE
  • 2.3. INDUSTRY STRUCTURE
  • 2.4. REGULATORY FRAMEWORK
  • 2.5. TOTAL MARKET ANALYSIS
    • 2.5.1. TOP 5 FINDINGS
    • 2.5.2. TOP 5 OPPORTUNITY MARKETS
    • 2.5.3. TOP 5 COMPANIES
    • 2.5.4. TOP 3 COMPETITIVE STRATEGIES
  • 2.6. ESTIMATION ANALYSIS
  • 2.7. STRATEGIC ANALYSIS
    • 2.7.1. INVESTMENT VS. ADOPTION MODEL
    • 2.7.2. 360-DEGREE INDUSTRY ANALYSIS
    • 2.7.3. PORTERS 5 FORCE MODEL
    • 2.7.4. SEE-SAW ANALYSIS
    • 2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
  • 2.8. COMPETITIVE ANALYSIS
    • 2.8.1. KEY STRATEGIES & ANALYSIS
    • 2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
  • 2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
    • 2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
    • 2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
    • 2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT

3. MARKET DETERMINANTS

  • 3.1. MARKET DRIVERS
    • 3.1.1. INCREASED DEMAND FOR SELF INJECTION DEVICES
    • 3.1.2. RISING PREVALENCE OF CHRONIC DISEASES
    • 3.1.3. TECHNOLOGICAL ADVANCEMENTS IN MEDICAL INDUSTRY
    • 3.1.4. NEW PRODUCT LAUNCHES
    • 3.1.5. GROWTH IN BIOLOGICS MARKET
  • 3.2. MARKET RESTRAINTS
    • 3.2.1. INFECTIONS ASSOCIATED WITH NEEDLLESTICK INJURIES
  • 3.3. MARKET OPPORTUNITIES
    • 3.3.1. INCREASING DEMAND FOR BIOSIMILAR AND GENERIC INJECTABLES
    • 3.3.2. INCREASING APPLICATIONS OF CONTRACEPTIVE INJECTABLES
  • 3.4. MARKET CHALLENGES
    • 3.4.1. PREFERENCE FOR OTHER MODES OF DRUG DELIVERY

4. MARKET SEGMENTATION

    • 4.1.1. INJECTABLE DRUG DELIVERY MARKET BY TYPE
    • 4.1.2. MARKET DEFINITION AND SCOPE
    • 4.1.3. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.1.4. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.1.5. OPPORTUNITY MATRIX
    • 4.1.6. MARKET SEGMENTATION
      • 4.1.6.1. GLOBAL DEVICES MARKET
        • 4.1.6.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.6.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.6.1.3. TOP PLAYERS & KEY PRODUCTS
        • 4.1.6.1.4. KEY CONCLUSIONS
      • 4.1.6.2. GLOBAL FORMULATIONS MARKET
        • 4.1.6.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.1.6.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.1.6.2.3. TOP PLAYERS & KEY PRODUCTS
        • 4.1.6.2.4. KEY CONCLUSIONS
  • 4.2. INJECTABLE DRUG DELIVERYMARKET BY FORMULATION
    • 4.2.1. MARKET DEFINITION AND SCOPE
    • 4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.2.4. OPPORTUNITY MATRIX
    • 4.2.5. MARKET SEGMENTATION
      • 4.2.5.1. GLOBAL AMPULES MARKET
        • 4.2.5.1.1. APPLICATION
        • 4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.1.5. KEY CONCLUSIONS
      • 4.2.5.2. GLOBAL BOTTLES MARKET
        • 4.2.5.2.1. APPLICATION
        • 4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.2.5. KEY CONCLUSIONS
      • 4.2.5.3. GLOBAL CARTRIDGES MARKET
        • 4.2.5.3.1. APPLICATION
        • 4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.3.5. KEY CONCLUSIONS
      • 4.2.5.4. GLOBAL VIALS MARKET
        • 4.2.5.4.1. APPLICATION
        • 4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.2.5.4.5. KEY CONCLUSIONS
  • 4.3. INJECTABLE DRUG DELIVERYMARKET BY THERAPEUTIC APPLICATION
    • 4.3.1. MARKET DEFINITION AND SCOPE
    • 4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.3.4. OPPORTUNITY MATRIX
    • 4.3.5. MARKET SEGMENTATION
      • 4.3.5.1. GLOBAL AUTO IMMUNE DISEASES MARKET
        • 4.3.5.1.1. APPLICATION
        • 4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.1.5. KEY CONCLUSIONS
      • 4.3.5.2. GLOBAL HORMONAL DISORDERS MARKET
        • 4.3.5.2.1. APPLICATION
        • 4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.2.5. KEY CONCLUSIONS
      • 4.3.5.3. GLOBAL ONCOLOGY MARKET
        • 4.3.5.3.1. APPLICATION
        • 4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.3.5. KEY CONCLUSIONS
      • 4.3.5.4. GLOBAL ORPHAN DISEASES MARKET
        • 4.3.5.4.1. APPLICATION
        • 4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.4.5. KEY CONCLUSIONS
      • 4.3.5.5. GLOBAL OTHERS MARKET
        • 4.3.5.5.1. APPLICATION
        • 4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
        • 4.3.5.5.5. KEY CONCLUSIONS
  • 4.4. INJECTABLE DRUG DELIVERYMARKET BY USAGE PATTERN
    • 4.4.1. MARKET DEFINITION AND SCOPE
    • 4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.4.4. OPPORTUNITY MATRIX
    • 4.4.5. MARKET SEGMENTATION
      • 4.4.5.1. GLOBAL CURATIVE CARE MARKET
        • 4.4.5.1.1. APPLICATION
        • 4.4.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.4.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.4.5.1.5. KEY CONCLUSIONS
      • 4.4.5.2. GLOBAL IMMUNIZATION MARKET
        • 4.4.5.2.1. APPLICATION
        • 4.4.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.4.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.4.5.2.5. KEY CONCLUSIONS
      • 4.4.5.3. GLOBAL OTHERS MARKET
        • 4.4.5.3.1. APPLICATION
        • 4.4.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.4.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.4.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.4.5.3.5. KEY CONCLUSIONS
  • 4.5. INJECTABLE DRUG DELIVERYMARKET BY END USER
    • 4.5.1. MARKET DEFINITION AND SCOPE
    • 4.5.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
    • 4.5.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
    • 4.5.4. OPPORTUNITY MATRIX
    • 4.5.5. MARKET SEGMENTATION
      • 4.5.5.1. GLOBAL HOSPITALS MARKET
        • 4.5.5.1.1. APPLICATION
        • 4.5.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.5.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.5.5.1.4. TOP PLAYERS & KEY PRODUCTS
        • 4.5.5.1.5. KEY CONCLUSIONS
      • 4.5.5.2. GLOBAL HOMECARE MARKET
        • 4.5.5.2.1. APPLICATION
        • 4.5.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.5.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.5.5.2.4. TOP PLAYERS & KEY PRODUCTS
        • 4.5.5.2.5. KEY CONCLUSIONS
      • 4.5.5.3. GLOBAL OTHERS (RESEARCH INSTITUTES, CLINICAL, DIAGNOSTIC LABORATORIES) MARKET
        • 4.5.5.3.1. APPLICATION
        • 4.5.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
        • 4.5.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
        • 4.5.5.3.4. TOP PLAYERS & KEY PRODUCTS
        • 4.5.5.3.5. KEY CONCLUSIONS

5. COMPETITIVE LANDSCAPE

  • 5.1. KEY STRATEGIES
    • 5.1.1. LIST OF MERGERS AND ACQUISITION
    • 5.1.2. LIST OF JOINT VENTURES
    • 5.1.3. LIST OF PRODUCT LAUNCHES
    • 5.1.4. LIST OF PARTNERSHIPS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
  • 6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
  • 6.3. OPPORTUNITY MATRIX
  • 6.4. GLOBAL INJECTABLE DRUG DELIVERYMARKET BY REGION 2014-2023 ($ MILLION)
    • 6.4.1. NORTH AMERICA
      • 6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.1.2. TOP COUNTRY ANALYSIS
        • 6.4.1.2.1. U.S.
          • 6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.1.3. KEY CONCLUSIONS
        • 6.4.1.2.2. CANADA
          • 6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.1.2.2.3. KEY CONCLUSIONS
    • 6.4.2. EUROPE
      • 6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.2.2. TOP COUNTRY ANALYSIS
        • 6.4.2.2.1. UK
          • 6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.1.3. KEY CONCLUSIONS
        • 6.4.2.2.2. FRANCE
          • 6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.2.3. KEY CONCLUSIONS
        • 6.4.2.2.3. GERMANY
          • 6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.3.3. KEY CONCLUSIONS
        • 6.4.2.2.4. SPAIN
          • 6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.4.3. KEY CONCLUSIONS
        • 6.4.2.2.5. REST OF EUROPE
          • 6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.2.2.5.3. KEY CONCLUSIONS
    • 6.4.3. ASIA PACIFIC
      • 6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.3.2. TOP COUNTRY ANALYSIS
        • 6.4.3.2.1. CHINA
          • 6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.1.3. KEY CONCLUSIONS
        • 6.4.3.2.2. INDIA
          • 6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.2.3. KEY CONCLUSIONS
        • 6.4.3.2.3. JAPAN
          • 6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.3.3. KEY CONCLUSIONS
        • 6.4.3.2.4. AUSTRALIA
          • 6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.4.3. KEY CONCLUSIONS
        • 6.4.3.2.5. REST OF ASIA PACIFIC
          • 6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.3.2.5.3. KEY CONCLUSIONS
    • 6.4.4. ROW
      • 6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
      • 6.4.4.2. TOP COUNTRY ANALYSIS
        • 6.4.4.2.1. LATIN AMERICA
          • 6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.1.3. KEY CONCLUSIONS
        • 6.4.4.2.2. MIDDLE EAST & AFRICA
          • 6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
          • 6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
          • 6.4.4.2.2.3. KEY CONCLUSIONS

7. COMPANY PROFILES

  • 7.1. BECTON DICKINSON AND COMPANY (U.S.)
    • 7.1.1. OVERVIEW
    • 7.1.2. PRODUCT PORTFOLIO
    • 7.1.3. KEY INNOVATION SECTOR
    • 7.1.4. STRATEGIC INITIATIVES
    • 7.1.5. SCOT ANALYSIS
    • 7.1.6. STRATEGIC ANALYSIS
  • 7.2. BAXTER INTERNATIONAL (U.S.)
    • 7.2.1. OVERVIEW
    • 7.2.2. PRODUCT PORTFOLIO
    • 7.2.3. KEY INNOVATION SECTOR
    • 7.2.4. STRATEGIC INITIATIVES
    • 7.2.5. SCOT ANALYSIS
    • 7.2.6. STRATEGIC ANALYSIS
  • 7.3. PFIZER (U.S.)
    • 7.3.1. OVERVIEW
    • 7.3.2. PRODUCT PORTFOLIO
    • 7.3.3. KEY INNOVATION SECTOR
    • 7.3.4. STRATEGIC INITIATIVES
    • 7.3.5. SCOT ANALYSIS
    • 7.3.6. STRATEGIC ANALYSIS
  • 7.4. GERRESHEIMER AG (GERMANY)
    • 7.4.1. OVERVIEW
    • 7.4.2. PRODUCT PORTFOLIO
    • 7.4.3. KEY INNOVATION SECTOR
    • 7.4.4. STRATEGIC INITIATIVES
    • 7.4.5. SCOT ANALYSIS
    • 7.4.6. STRATEGIC ANALYSIS
  • 7.5. SCHOTT AG (GERMANY)
    • 7.5.1. OVERVIEW
    • 7.5.2. PRODUCT PORTFOLIO
    • 7.5.3. KEY INNOVATION SECTOR
    • 7.5.4. STRATEGIC INITIATIVES
    • 7.5.5. SCOT ANALYSIS
    • 7.5.6. STRATEGIC ANALYSIS
  • 7.6. ELI LILLY AND COMPANY (U.S.)
    • 7.6.1. OVERVIEW
    • 7.6.2. PRODUCT PORTFOLIO
    • 7.6.3. KEY INNOVATION SECTOR
    • 7.6.4. STRATEGIC INITIATIVES
    • 7.6.5. SCOT ANALYSIS
    • 7.6.6. STRATEGIC ANALYSIS
  • 7.7. TERUMO CORPORATION (U.S.)
    • 7.7.1. OVERVIEW
    • 7.7.2. PRODUCT PORTFOLIO
    • 7.7.3. KEY INNOVATION SECTOR
    • 7.7.4. STRATEGIC INITIATIVES
    • 7.7.5. SCOT ANALYSIS
    • 7.7.6. STRATEGIC ANALYSIS
  • 7.8. ANTARES PHARMA INC. (U.S.)
    • 7.8.1. OVERVIEW
    • 7.8.2. PRODUCT PORTFOLIO
    • 7.8.3. KEY INNOVATION SECTOR
    • 7.8.4. STRATEGIC INITIATIVES
    • 7.8.5. SCOT ANALYSIS
    • 7.8.6. STRATEGIC ANALYSIS
  • 7.9. HOSPIRA INC. (U.S.)
    • 7.9.1. OVERVIEW
    • 7.9.2. PRODUCT PORTFOLIO
    • 7.9.3. KEY INNOVATION SECTOR
    • 7.9.4. STRATEGIC INITIATIVES
    • 7.9.5. SCOT ANALYSIS
    • 7.9.6. STRATEGIC ANALYSIS
  • 7.10. NONO NORDISK (DENMARK)
    • 7.10.1. OVERVIEW
    • 7.10.2. PRODUCT PORTFOLIO
    • 7.10.3. KEY INNOVATION SECTOR
    • 7.10.4. STRATEGIC INITIATIVES
    • 7.10.5. SCOT ANALYSIS
    • 7.10.6. STRATEGIC ANALYSIS
  • 7.11. SANOFI SA (FRANCE)
    • 7.11.1. OVERVIEW
    • 7.11.2. PRODUCT PORTFOLIO
    • 7.11.3. KEY INNOVATION SECTOR
    • 7.11.4. STRATEGIC INITIATIVES
    • 7.11.5. SCOT ANALYSIS
    • 7.11.6. STRATEGIC ANALYSIS
  • 7.12. SCANDINAVIAN HEALTH LTD. (TAIWAN)
    • 7.12.1. OVERVIEW
    • 7.12.2. PRODUCT PORTFOLIO
    • 7.12.3. KEY INNOVATION SECTOR
    • 7.12.4. STRATEGIC INITIATIVES
    • 7.12.5. SCOT ANALYSIS
    • 7.12.6. STRATEGIC ANALYSIS
  • 7.13. TERUMO CORPORATION (JAPAN)
    • 7.13.1. OVERVIEW
    • 7.13.2. PRODUCT PORTFOLIO
    • 7.13.3. KEY INNOVATION SECTOR
    • 7.13.4. STRATEGIC INITIATIVES
    • 7.13.5. SCOT ANALYSIS
    • 7.13.6. STRATEGIC ANALYSIS
  • 7.14. UNILIFE CORPORATION (U.S.)
    • 7.14.1. OVERVIEW
    • 7.14.2. PRODUCT PORTFOLIO
    • 7.14.3. KEY INNOVATION SECTOR
    • 7.14.4. STRATEGIC INITIATIVES
    • 7.14.5. SCOT ANALYSIS
    • 7.14.6. STRATEGIC ANALYSIS
  • 7.15. ZOGENIX INC. (U.S.)
    • 7.15.1. OVERVIEW
    • 7.15.2. PRODUCT PORTFOLIO
    • 7.15.3. KEY INNOVATION SECTOR
    • 7.15.4. STRATEGIC INITIATIVES
    • 7.15.5. SCOT ANALYSIS
    • 7.15.6. STRATEGIC ANALYSIS

LIST OF TABLES

  • Table 1. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY TYPE 2014-2023 ($ MILLION)
  • Table 2. GLOBAL DEVICES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 3. GLOBAL FORMULATIONS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 4. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY FORMULATION2014-2023 ($ MILLION)
  • Table 5. GLOBAL AMPULES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 6. GLOBAL BOTTLES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 7. GLOBAL CARTRIDGES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 8. GLOBAL VIALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 9. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY THERAPEUTIC APPLICATION 2014-2023 ($ MILLION)
  • Table 10. GLOBAL AUTO IMMUNE DISEASES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 11. GLOBAL HORMONAL DISORDERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 12. GLOBAL ONCOLOGY MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 13. GLOBAL ORPHAN DISEASES MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 14. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 15. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY USAGE PATTERN2014-2023 ($ MILLION)
  • Table 16. GLOBAL CURATIVE CARE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 17. GLOBAL IMMUNIZATION MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 18. GLOBAL OTHERS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 19. GLOBAL INJECTABLE DRUG DELIVERY MARKET BY END USER 2014-2023 ($ MILLION)
  • Table 20. GLOBAL HOSPITALS MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 21. GLOBAL HOMECARE MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 22. GLOBAL OTHERS (RESEARCH INSTITUTES, CLINICAL, DIAGNOSTIC LABORATORIES) MARKET BY GEOGRAPHY 2014-2023 ($ MILLION)
  • Table 23. NORTH AMERICA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Table 24. EUROPE INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Table 25. ASIA PACIFIC INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Table 26. REST OF THE WORLD INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)

LIST OF FIGURES

  • Figure 1. GLOBAL INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 2. GLOBAL DEVICES MARKET 2014-2023 ($ MILLION)
  • Figure 3. GLOBAL FORMULATIONS MARKET 2014-2023 ($ MILLION)
  • Figure 4. GLOBAL AMPULES MARKET 2014-2023 ($ MILLION)
  • Figure 5. GLOBAL BOTTLES MARKET 2014-2023 ($ MILLION)
  • Figure 6. GLOBAL CARTRIDGES MARKET 2014-2023 ($ MILLION)
  • Figure 7. GLOBAL VIALS MARKET 2014-2023 ($ MILLION)
  • Figure 8. GLOBAL AUTO IMMUNE DISEASES MARKET 2014-2023 ($ MILLION)
  • Figure 9. GLOBAL HORMONAL DISORDERS MARKET 2014-2023 ($ MILLION)
  • Figure 10. GLOBAL ONCOLOGY MARKET 2014-2023 ($ MILLION)
  • Figure 11. GLOBAL ORPHAN DISEASES MARKET 2014-2023 ($ MILLION)
  • Figure 12. GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
  • Figure 13. GLOBAL CURATIVE CARE MARKET 2014-2023 ($ MILLION)
  • Figure 14. GLOBAL IMMUNIZATION MARKET 2014-2023 ($ MILLION)
  • Figure 15. GLOBAL OTHERS MARKET 2014-2023 ($ MILLION)
  • Figure 16. GLOBAL HOSPITALS MARKET 2014-2023 ($ MILLION)
  • Figure 17. GLOBAL HOMECARE MARKET 2014-2023 ($ MILLION)
  • Figure 18. GLOBAL OTHERS (RESEARCH INSTITUTES, CLINICAL, DIAGNOSTIC LABORATORIES) MARKET 2014-2023 ($ MILLION)
  • Figure 19. UNITED STATES (U.S.) INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 20. CANADA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 21. UNITED KINGDOM (UK) INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 22. FRANCE INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 23. GERMANY INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 24. SPAIN INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 25. ROE INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 26. INDIA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 27. CHINA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 28. JAPAN INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 29. AUSTRALIA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 30. ROAPAC INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 31. LATIN AMERICA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)
  • Figure 32. MENA INJECTABLE DRUG DELIVERY MARKET 2014-2023 ($ MILLION)